2.5 Million in Sierra Leone Receive Anti-Malarial Medicines in Emergency Response Campaign

Article

Two successive emergency response campaigns in Sierra Leone to distribute anti-malarial drugs to people living in areas affected by the Ebola virus disease outbreak have successfully reached more than 2.5 million people, and significantly reduced the number of people with fever that might be mistaken for Ebola virus disease (EVD).

More than 2.5 million people reached in emergency response campaign with anti-malarial medicines in Sierra Leone.

Two successive emergency response campaigns in Sierra Leone to distribute anti-malarial drugs to people living in areas affected by the Ebola virus disease outbreak have successfully reached more than 2.5 million people, and significantly reduced the number of people with fever that might be mistaken for Ebola virus disease (EVD).

During the West African Ebola outbreak, people infected with malaria have been afraid to go to health centres for treatment or have been unable to receive treatment because some health centres were closed. To reduce malaria transmission and related deaths, the World Health Organization (WHO) recommended a mass drug administration of anti-malarial medicines to all eligible people in Ebola hotspot areas.

“This intervention was done to reduce the number of febrile patients in the community so that people with fever caused by malaria would not be sent to the Ebola holding centres where they would be at risk of contracting Ebola,” says Dr. Daniel Kertesz, the WHO representative in Sierra Leone.

“Malaria is a major public health problem in Sierra Leone causing thousands of deaths every year. With the current Ebola outbreak and its impact on the health system, we estimate that without this sort of pre-emptive intervention, malaria deaths could potentially double,” says Dr. Pedro Alonso, director of the WHO Global Malaria Program.

A total of 8,330 health workers were mobilized for the door-to-door distribution in eight districts (Bombali, Kambia, Koinadugu, Moyamba, Port Loko and Tonkolili and Western Area - Urban and Rural). The campaign was implemented by the National Malaria Control Program of the Ministry of Health and Sanitation with technical support and guidance by WHO in collaboration with MSF, UNICEF and other Roll Back Malaria partners.

Alonso and the team have completed a preliminary assessment of the two malaria campaigns in the country. “While a detailed assessment of the achieved impact will be completed over the next few weeks, we have reasons to believe that the distribution of the anti-malarial medicines has a profound positive impact on the transmission of malaria and the number of suspected cases attending Ebola holding centres,” says Alonso. “The community responded very positively - so positively that numbers of people wishing to receive the anti-malarial medicines were higher than expected."

Source: WHO

Recent Videos
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Infection Control Today's Infection Intel: Staying Ahead With Company Updates and Product Innovations.
COVID-19 presentations at IDWeek in Las Angeles, California by Invivyd.   (Adobe Stock 333039083 by Production Perig)
Long COVID and Other Post-Viral Syndromes
Meet Jenny Hayes, MSN, RN, CIC, CAIP, CASSPT.
Infection Control Today Editorial Advisory Board: Fibi Attia, MD, MPH, CIC.
Andrea Thomas, PhD, DVM, MSc, BSc, director of epidemiology at BlueDot
mpox   (Adobe Stock 924156809 by Andreas Prott)
Meet Alexander Sundermann, DrPH, CIC, FAPIC.
Related Content